Skip to main content
NewslettersWatchlist

Amphastar Pharma(AMPH-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low44.71
Day High45.90
Open:45.48
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
ACCESSWIRE
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6, 2024
ACCESSWIRE
Amphastar Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference
ACCESSWIRE
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
ACCESSWIRE
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2023
ACCESSWIRE
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2023
ACCESSWIRE
Amphastar Pharmaceuticals Announces Pricing of Offering of $300.0 Million of Convertible Senior Notes
ACCESSWIRE
Amphastar Pharmaceuticals Announces Proposed Private Offering of $300.0 Million of Convertible Senior Notes
ACCESSWIRE
Amphastar Pharmaceuticals to Present at the Wells Fargo Healthcare Conference
OTOS Inc.
Betting Big On Biotech: Six Undervalued Biotech Stocks To Keep On Your Radar
ACCESSWIRE
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2023
ACCESSWIRE
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2023
ACCESSWIRE
Amphastar Pharmaceuticals Completes Acquisition of BAQSIMI from Lilly
MarketBeat
Promising Small Biotech Amphastar Sees Actionable Pullback
ACCESSWIRE
Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference
ACCESSWIRE
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2023
ACCESSWIRE
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2023
PR Newswire
Lilly to Divest BAQSIMI to Amphastar
ACCESSWIRE
Amphastar Pharmaceuticals Business Update and Hold Conference Call on April 24th, 2023
ACCESSWIRE
Amphastar Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
ACCESSWIRE
Amphastar Pharmaceuticals Receives FDA Approval for Naloxone Hydrochloride Nasal Spray 4mg
Motley Fool
Why Shares of Amphastar Pharmaceuticals Rose Today
ACCESSWIRE
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2023

Profile

Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright ยฉ 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright ยฉ 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.